Company news
Resverlogix Corp. news in 2008
Resverlogix Corp.'s news releases, calls and decks from 2008, newest first.
Resverlogix Board of Directors Update
November 26, 2008
RVX-208 Data Demonstrates Increase in Functional HDL Particles
November 10, 2008
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
November 10, 2008
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
October 21, 2008
Resverlogix Announces Closing of Debt Redemption
October 17, 2008
Resverlogix Eliminates Sixty Percent of Remaining Debt
October 15, 2008
Resverlogix Issues a Management Statement
October 7, 2008
International Steering Committee for RVX-208 IVUS Trial Formed
October 7, 2008
ApoA-I Data Presented at European Society of Cardiology Congress
September 2, 2008
Phase 1b/2a Program Commences for RVX-208
August 25, 2008
Resverlogix Notice of Conference Call & Webcast
August 21, 2008
Jan Gray Joins Resverlogix Board of Directors
July 25, 2008
Resverlogix's Lead Drug Featured in Key Scientific Publication
July 18, 2008
Industry Leaders Select Resverlogix's RVX-208
July 9, 2008
Resverlogix to Collaborate with Cleveland Clinic
June 19, 2008
Key Primary Resverlogix Objective Obtained
June 18, 2008
/C O R R E C T I O N from Source -- Resverlogix Corp./
May 1, 2008
Dosing for RVX-208 Phase 1a Clinical Study Completed
April 22, 2008
Resverlogix Share Option Extension
April 21, 2008
Progress Report from RVX-208 Phase 1 Clinical Study
January 14, 2008